Galectin Therapeutics Inc.
GALT
Price:
$2.67
Market Cap:
$175.84M
Galectin Therapeutics Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and advancing new therapies for a spectrum of illnesses, including fibrotic disorders and various cancers. The company's flagship therapeutic agent is belapectin (GR-MD-02), an inhibitor of galectin-3, which is a complex polysaccharide polymer. This compound is currently undergoing Phase III clinical trials, assessing its effectiveness in treating liver scarring linked to fatty liver disease and non-alcoholic steatohepatitis (NASH) cirrhosis, alongside its potential for cancer treatment. Beyond belapectin, Galectin Therapeutics is progressing GM-CT-01 through preclinical stag...[Read more]
Industry
Biotechnology
IPO Date
2002-09-04
Stock Exchange
NASDAQ
Ticker
GALT
PE Ratio
[-6.51]
ROE
[21.05%]
Current Ratio
[2.15]
Dividend Yield
[0%]
Enterprise Value
[297.44M]
Dividend History
The ROE as of June 2026 (TTM) for Galectin Therapeutics Inc. (GALT) is 21.05%
According to Galectin Therapeutics Inc.’s latest financial reports and current stock price. The company's current ROE is 21.05%. This represents a change of 297.43% compared to the average of 5.30% of the last 4 quarters.
Galectin Therapeutics Inc. (GALT) Historical ROE (quarterly & annually)
How has GALT ROE performed in the past?
The mean historical ROE of Galectin Therapeutics Inc. over the last ten years is -277.52%. The current 21.05% ROE has changed -107.58% with respect to the historical average. Over the past ten years (40 quarters), GALT's ROE was at its highest in in the March 2022 quarter at 160.37%. The ROE was at its lowest in in the December 2021 quarter at -276.03%.
Average
-277.52%
Median
-63.07%
Minimum
-1360.85%
Maximum
120.44%
Galectin Therapeutics Inc. (GALT) ROE by Quarter and Year
Discovering the peaks and valleys of Galectin Therapeutics Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 1.10%
Maximum Annual ROE = 120.44%
Minimum Annual Increase = -110.32%
Minimum Annual ROE = -1360.85%
| Year | ROE | Change |
|---|---|---|
| 2025 | 24.44% | -46.47% |
| 2024 | 45.65% | -33.04% |
| 2023 | 68.17% | -43.40% |
| 2022 | 120.44% | -110.32% |
| 2021 | -1166.93% | 1.10% |
| 2020 | -96.99% | 232.65% |
| 2019 | -29.16% | -85.53% |
| 2018 | -201.51% | -85.19% |
| 2017 | -1360.85% | 662.77% |
| 2016 | -178.41% | 123.14% |
Galectin Therapeutics Inc. (GALT) Average ROE
How has GALT ROE performed in the past?
The current ROE of Galectin Therapeutics Inc. (GALT) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
46.08%
5-year avg
-181.65%
10-year avg
-277.52%
Galectin Therapeutics Inc. (GALT) ROE vs. Peers
How is GALT’s ROE compared to its peers?
Galectin Therapeutics Inc.’s ROE is greater than I-Mab (-0.50%), greater than DiaMedica Therapeutics Inc. (-77.09%), greater than Design Therapeutics, Inc. (-33.07%), greater than Rocket Pharmaceuticals, Inc. (-70.79%), greater than Aura Biosciences, Inc. (-78.12%), greater than Alpha Tau Medical Ltd. (-73.23%), greater than enGene Holdings Inc. (-55.83%), greater than LB Pharmaceuticals Inc Common Stock (-17.68%), greater than Altimmune, Inc. (-42.57%), greater than Quantum-Si incorporated (-47.35%),
| Company | ROE | Market cap |
|---|---|---|
| -0.50% | $542.01M | |
| -77.09% | $304.44M | |
| -33.07% | $685.15M | |
| -70.79% | $300.28M | |
| -78.12% | $411.52M | |
| -73.23% | $889.71M | |
| -55.83% | $82.94M | |
| -17.68% | $814.99M | |
| -42.57% | $230.35M | |
| -47.35% | $187.28M |
Build a custom stock screener for Galectin Therapeutics Inc. (GALT) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Galectin Therapeutics Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Galectin Therapeutics Inc. (GALT) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Galectin Therapeutics Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Galectin Therapeutics Inc.'s ROE?
How is the ROE calculated for Galectin Therapeutics Inc. (GALT)?
What is the highest ROE for Galectin Therapeutics Inc. (GALT)?
What is the 3-year average ROE for Galectin Therapeutics Inc. (GALT)?
What is the 5-year average ROE for Galectin Therapeutics Inc. (GALT)?
How does the current ROE for Galectin Therapeutics Inc. (GALT) compare to its historical average?